OR6A2 on Monocytes and Cardiovascular Outcomes in Myocardial Ischemia-Reperfusion Injury
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Blood Biomarker Profiling and Prognostic Follow-up.
- Who it may be relevant to
- Registry conditions: Myocardial Ischemia-Reperfusion Injury. Basic parameters: 18 years — 90 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Association of OR6A2 Expression on Monocytes With Inflammation and Major Adverse Cardiovascular Events in Myocardial Ischemia-Reperfusion Injury
Overview
This study examines how the interaction between octanal (an OR6A2 receptor activator) and OR6A2 expression influences inflammation and clinical outcomes in Myocardial Ischemia-Reperfusion Injury patients. We analyze two key relationships: 1) The octanal-OR6A2 pathway's association with systemic oxidative stress/inflammatory biomarkers, and 2) How OR6A2 expression patterns on monocyte subtypes and plasma octanal levels correlate with major cardiovascular events. Patients undergoing this post-revascularization injury provided blood samples for OR6A2/octanal/inflammation measurements. IR Injury patients underwent 44-month clinical follow-up. Results may identify biological markers for personalized risk assessment after revascularization therapies. Ethics approval: Zhongda Hospital #2020ZDSYLL051-P01.
Interventions
- Diagnostic test Blood Biomarker Profiling and Prognostic Follow-up
Peripheral venous blood collection for in-vitro quantification of serum biomarkers (including octanal, OR6A2, and inflammatory mediators) via mass spectrometry/ELISA/flow cytometry, coupled with longitudinal surveillance of Major Adverse Cardiovascular Events (MACEs) using hospital records, patient interviews, and adjudicated endpoint verification during scheduled follow-up visits.
Primary outcome measures
- Major Adverse Cardiovascular Events [Time frame: From enrollment to 44 months after reperfusion injury]
Secondary outcome measures (4)
- Serum IL-1α Level [Time frame: Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury)]
- Serum IL-1β Level [Time frame: Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury)]
- Plasma Malondialdehyde (MDA) Level [Time frame: Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury)]
- Plasma Hydrogen Peroxide (H₂O₂) Level [Time frame: Baseline (within 24 hours after confirmed myocardial ischemia-reperfusion injury)]
Eligibility criteria
Inclusion criteria
- Acute myocardial infarction (AMI) patients with angiographically-confirmed coronary artery disease undergoing primary percutaneous coronary intervention (PCI), and subsequently diagnosed with protocol-defined myocardial ischemia-reperfusion injury during the post-PCI period.
- Age 18-90 years inclusive.
Exclusion criteria
- Active systemic infections.
- Advanced heart failure (NYHA class III-IV).
- Acute cerebrovascular conditions.
- Active myocarditis.
- cardiomyopathy.
- Refractory ventricular tachycardia/fibrillation.
- Diagnosis/concurrent treatment for malignancy within 5 years (except non-melanoma skin cancer/carcinoma in situ).
- Severe renal insufficiency (estimated glomerular filtration rate \[eGFR\] <30 mL/min/1.73m2 or dialysis dependence).
- Child-Pugh class C hepatic dysfunction.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Department of Cardiology, Zhongda Hospital, Southeast University — Nanjing
Publications
- Zhang Y, Xiao T, Ding J, Jin H, Wu Y, Villamil OIRC, Wang D, Yang M, Cai J, Ma G, Lu W. Targeting olfactory receptor 2 on monocytes for cardioprotection against myocardial ischaemia-reperfusion injury via NR4A1-mediated mitochondrial fission. Cardiovasc Res. 2025 Dec 31;121(17):2759-2776. doi: 10.1093/cvr/cvaf232. PMID 41223038
Identifiers
NCT: NCT07100457 · 2020ZDSYLL051-P01